|
Mg123 ; . The only adverse reaction was a grade 1 hypersensitivity to cold lasting up to a week. The seventh cycle was also administered without complication. Then during the eighth cycle, 30 minutes into the 4-hour infusion of oxaliplatin running at 135 mL h 27 mg ; , the patient was noted to have grade 2 facial flushing and grade 4 shortness of breath at rest, and the infusion was stopped immediately. The patient complained of dyspnea and chest tightness both grade 1 ; , and his lips appeared slightly cyanotic. He received additional i.v. push diphenhydramine 50 mg ; , dexamethasone 20 mg ; , famotidine 20 mg ; , and subcutaneous administration of epinephrine 0.5 mg ; . Within 15-20 minutes the symptoms had resolved, except for grade 1 rigors, for which i.v. push meperidine hyrochloride 25 mg ; was given with relief. The patient was observed for the next three hours, and discharged home with his family. The hypersensitivity reaction was graded as a 3. After a severe hypersensitivity reaction grade 3 or higher ; , the only option to continue oxaliplatin treatment would be desensitization [4, 9, 10]. However, due to the potential fatality and subsequent issues i.e. the need for an intensive care unit bed ; , other options were pursued. The patient's excellent response to the GemOx regimen partial response: 48% decrease in tumor, including disappearance of all lung nodules; CA 19-9 dropped from 52.3 to 34.4 U mL reference range 0-37 U mL ; warranted the consideration of using another platinum salt, such as cisplatin [11]. In order to rule out the possibility of platinum cross-reactivity, a cisplatin skin test was administered on the patient, 0.04 mL intradermally on the volar surface of the arm. The result was negative and so he was treated 75 minutes later with the new regimen of gemcitabine 1, 000 mg m2 ; and cisplatin 50 mg m2 ; . The gemcitabine was administered over 30-minute infusion followed by a 1-hour infusion of cisplatin; premedications included ondansetron 16 mg ; , dexamethasone 20 mg ; , lorazepam 0.5 mg also, 3-hour cisplatin hydration 1, 000 mL ; infusion was.
811 On the behalf of BIG 1-98 Collaborative Group and International Breast Cancer Study Group, Berne, Switzerland Autoantibodies in breast cancer: their use as an aid to early diagnosis C. Chapman, A. Murray, J. Chakrabarti, A. Thorpe, C. Woolston, U. Sahin, A. Barnes & J. Robertson Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers C. Mazouni, S.-W. Kau, D. Frye, F. Andre, H. M. Kuerer, T. A. Buchholz, W. F. Symmans, K. Anderson, K. R. Hess, A. M. Gonzalez-Angulo, G. N. Hortobagyi, A. U. Buzdar & L. Pusztai Gynecologic tumors Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome J. M. Riedinger, F. Bonnetain, J. P. Basuyau, N. Eche, H. Larbre, I. Dalifard, J. Wafflart, G. Ricolleau & M. F. Pichon 881 Gastrointestinal tumors Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma J. Lee, T. Lim, J. E. Uhm, K. W. Park, S. H. Park, S. C. Lee, J. O. Park, Y. S. Park, H. Y. Lim, T. S. Sohn, J. H. Noh, J. S. Heo, C. K. Park, S. Kim & W. K. Kang Gene amplification and protein overexpression of HER-2 neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients H. J. Kim, T. W. Yoo, D. I. Park, J. H. Park, Y. K. Cho, C. I. Sohn, W. K. Jeon, B. I. Kim, M. K. Kim, S. W. Chae & J. H. Sohn Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer D. H. Ilson, R. G. Wadleigh, L. P. Leichman & D. P. Kelsen Lung cancer Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone S. Novello, P. Bruzzi, C. Barone, R. Buosi, A. Masotti, G. Michetti, M. Fioretti, S. Barbera, M. Spatafora, L. Garetto, P. Mazzanti, V. Dongiovanni, G. Selvaggi, L. Crin & G. V. Scagliotti 903.
A hoosier oncology group hog ; study will evaluate this three-drug regimen v cisplatin plus etoposide , and this protocol will establish or refute the value of ifosfamide as first-line therapy in extensive sclc.
1443 ; Mathur S, Devaraj S, Grundy SM, Jialal I. Cocoa products decrease low density lipoprotein oxidative susceptibility but do not affect biomarkers of inflammation in humans. J Nutr 2002 December; 132 12 ; : 3663-7. 1444 ; Melzig MF, Loser B, Ciesielski S. Inhibition of neutrophil elastase activity by phenolic compounds from plants. Pharmazie 2001 December; 56 12 ; : 967-70. 1445 ; Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000 December; 52 4 ; : 673-751. 1446 ; Njamen D, Mbafor JT, Fomum ZT et al. Anti-inflammatory activities of two flavanones, sigmoidin A and sigmoidin B, from Erythrina sigmoidea. Planta Med 2004 February; 70 2 ; : 104-7. 1447 ; Olszanecki R, Gebska A, Kozlovski VI, Gryglewski RJ. Flavonoids and nitric oxide synthase. J Physiol Pharmacol 2002 December; 53 4 Pt 1 ; 571-84. 1448 ; Sovak M. Grape Extract, Resveratrol, and Its Analogs: A Review. J Med Food 2001; 4 2 ; : 93-105. 1449 ; Varilek GW, Yang F, Lee EY et al. Green tea polyphenol extract attenuates inflammation in interleukin-2-deficient mice, a model of autoimmunity. J Nutr 2001 July; 131 7 ; : 2034-9. 1450 ; Villar A, Gasco MA, Alcaraz MJ. Anti-inflammatory and anti-ulcer properties of hypolaetin-8-glucoside, a novel plant flavonoid. J Pharm Pharmacol 1984 December; 36 12 ; : 820-3. 1451 ; Yadava RN, Reddy VM. Anti-inflammatory activity of a novel flavonol glycoside from the Bauhinia variegata Linn. Nat Prod Res 2003 June; 17 3 ; : 1659. 1452 ; Yahiro K, Shirasaka D, Tagashira M et al. Inhibitory effects of polyphenols on gastric injury by Helicobacter pylori VacA toxin. Helicobacter 2005 June; 10 3 ; : 231-9. 1453 ; Abeywardena MY, Head RJ. Dietary polyunsaturated fatty acid and antioxidant modulation of vascular dysfunction in the spontaneously hypertensive rat. Prostaglandins Leukot Essent Fatty Acids 2001 August; 65 2 ; : 91-7. 1454 ; Bernatova I, Pechanova O, Babal P, Kysela S, Stvrtina S, Andriantsitohaina R. Wine polyphenols improve cardiovascular remodeling and vascular function in NO-deficient hypertension. J Physiol Heart Circ Physiol 2002 March; 282 3 ; : H942-H948. 1455 ; Himmel W, Lonker B, Kochen MM. [Relevance of general practitioner's prescriptions for hospital pharmacotherapy. A survey of hospital physicians]. Dtsch Med Wochenschr 1996 November 22; 121 47 ; : 1451-6.
A Randomized Phase II Study of Gemcitabine or Paclitaxel or Vinorelbine with Cisplatin as Induction Chemotherapy Ind CT ; and Concomitant Chemoradiotherapy XRT ; for Unresectable Stage III Non-Small Cell Lung Cancer NSCLC ; CALGB Study 9431 ; . EE Vokes, KA Leopold, JE Herndon II, J Crawford, MC Perry, AA Miller, MR Green. Cancer and Leukemia Group B, Chicago, Illinois. ABSTRACT 1771.
Whom well-developed cancerous growths had very largely disappeared under special feeding" J.H. Kellogg, New Dietetics, 915 ; . William J. Mayo, M.D., of the famed Mayo Clinic in Rochester, Minnesota, said this: "Is it not possible, therefore, that there is something in the habits of civilized man, in the cooking or other preparation of his food, which acts to produce the precancerous conditions? Within the last one hundred years, four times as much meat is taken as before that time. If flesh foods are not fully broken up, decomposition results, and active poisons are thrown into an organ not intended for their reception, and which has not had time to adapt itself to the new condition" W.J. Mayo, M.D., quoted in Life and Health, June 1935 ; . "Laboratory experience has repeatedly demonstrated the controlling effect of diet on cancer in animals. In one extensive series of experiments, 75 percent of 75 inoculated mice developed tumors while under normal diet; whereas only 19 percent of another 75 inoculated mice developed tumors under a diet with vegetable proteins. Moreover, the tumors in the udder were hardly larger in 30 days than those in the former in ten days" L. Duncan Buckley, M.D., senior physician in the New York Skin and Cancer Hospital, as reported in Oriental Watchman and Herald of Health, May 1938 and cladribine.
Data. The molecular nature of cisplatin-induced mutations was previously investigated by using either the histidine reversion assays in Salmonella typhimurium 16-20, 48 ; or the lacI forward-mutation assay in E. coli 14 ; . From the reversion assays in S. typhimurium, it was concluded that cisplatin was able to revert base-pair-substitution strains, provided plasmid pKM101 was present, but not frameshiftmutation strains 48 ; . In the present work, we analyzed all the mutants leading to the inactivation of the tetracycline-resistance gene. Previous studies with chemical carcinogens belonging to the family of aromatic amines have shown that the assay responds both to base-pair substitutions 26 ; and to frameshift mutations 25 ; , deletions, and insertions. Our results show that cisplatin induces a majority of A-T-- * T-A transversions, mainly at ApG sites. Brouwer et al. 14 ; found that cisplatin induces basepair-substitution hot spots in the lacd gene at GpApG and GpCpG sequences 70% of all the nonsense mutants ; , the mutations being either G-C- * A.T transitions or G-C-- * T-A transversions. At most, but not all, sites the mutated guanine residue was the one at the 5' side. The lacI mutation assay used by Brouwer et al. 14 ; is such that among all the induced mutants, only the molecular nature of the base substitutions leading to nonsense codons is analyzed. As found by these authors, this subclass of mutants represents only 13% of the collection of induced lad mutants.
Cisplatin xeloda
In thousands of euros. 2 ; I.e: Germany, Spain, France, Italy and United Kingdom. 3 ; Including North America and Asia. At 31 December 2006, of the 1, 216 people comprising the Group's sales force, 630 staff were employed outside the Major Western European Countries, i.e. 16.5% of the Group's workforce. A geographical analysis of the Group's workforce by job category and by therapeutic area is provided in Chapter 17 of this registration document on Employees. constituents into secondary formulations and the related packaging. Each stage of the manufacturing process takes place in strictly controlled conditions and is subject to the applicable national and international legislation. All the Group's manufacturing facilities comply with Good Manufacturing Practices GMP ; , in line with the relevant directives. Manufacturing facilities outside the United States, which import products into the country, must be approved by the FDA on a product-by-product basis and are subject to periodic inspections by the FDA. The Group manufactures its own products when it deems this to be necessary for its business for strategic reasons, but also relies upon outsourcing as an alternative for certain projects. Likewise, where appropriate, the Group enters into supply agreements with third parties, such as Expansia, a fine chemicals company that supplies certain active substances and clofarabine.
Updated recommendations on antiretroviral treatment for HIV infection by the International AIDS Society panel. HIV-1 sequence data was collected between March 1999 and May 2003, with some patients having sequences collected at more than one time point. Additional information on HIV transmission, ethnicity, sex and HBV and HCV infection status was also acquired Table 1.
GUIDELINES A. Except in the case of initial hiring, employees are eligible for up to three 3 ; personal days per year. Personal days may be taken any time during the calendar year subject to the advance approval of the employee's Supervisor or Service Unit Director. B. During the first calendar year of employment as a full-time employee, the following schedule shall apply: IF HIRED January - March April - June July - September October - December ELIGIBLE FOR 3 Days 2 Days 1 Day 0 None and clofibrate.
In cultured renal proximal tubular cells, cisplatin at 20mum induced an early p53 phosphorylation followed by protein accumulation.
Where D are the diffusion constants of Flutax and microtubules the diffusion coefficient for a molecule of the size of Flutax ~2x10-9 m diameter ; in an aqueous buffer containing 30% glycerol at 37C calculated using the Stokes-Einstein equation is 1.6 x 10-10 m2 s-1, while the value for the microtubule can be neglected ; , d s the reciprocal linear density of sites in the microtubule 6.15x10-10 m site ; , L is the length of the microtubule, r its radius 12x10-9 m ; . Considering a and clorazepate.
Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include: Prior Authorization: Elder Care Health Plan requires you, or your physician, to get prior authorization for certain drugs. This means that you will need to get approval from Elder Care Health Plan before you fill your prescriptions. If you don't get approval, Elder Care Health Plan may not cover the drug. Quantity Limits: For certain drugs, Elder Care Health Plan limits the amount of the drug that Elder Care Health Plan will cover. For example, Elder Care Health Plan provides 9 tablets in 30 days per prescription for Imitrex.
Some people make a New Year's Day resolution, others pick their birthday, and you can join in with others on No Smoking Day - the second Wednesday of every March - when up to a million smokers have a go. Any day will do, but choosing a date will help mental preparation and clove.
Proteomic analysis of urine from prostate cancer patients Irish Cancer Society 2006-2009 172, 000.00 Dr. William Watson Prostate cancer biomarker discovery Irish Cancer Society 2006-2009 630, 000.00 Dr. William Watson A targeted contrast media in Multiple Myeloma Irish Cancer Society Blue Skies Grant 2006 2008 160, 000.00 Prof. S. Eustace The life cycle of the Demodex Folliculorum Mite Mater College 2006 40, 000.00 Dr. Frank Powell, Dr. Peter Doran Hepatitis C Research Nurse ; Roche Pharmaceuticals 2006 70, 000.00 Dr. Jack Lambert Predictors of Post-Stroke Dementia Health Research Board, Health Services Award Molecular Population 1 11 2005-30 Mechanisms Studies 90, 000.00 Studies Dr. Lisa Kelly, Dr. Peter J Kelly.
Medium, and centrifuged for 5 min at 1750 g at 4C. The pelleted cells were washed twice, resuspended in medium, and disaggregated, and pellets of 107 viable cells were snap frozen in liquid nitrogen and stored at 80C. Extracts were prepared by homogenizing cell pellets in 5 ml ice-cold extraction buffer [50 mM Tris-HCl pH 8.3 ; , 0.5 mM EDTA disodium salt, 1 mM DTT, and 200 mM NaCl] with a T25 Ultra-Turrax homogenizer SH Scientific, Northumberland, United Kingdom ; fitted with an 8-mm head, then centrifuging for 5 min at 1750 g, 4C; the supernatant was snap frozen and stored at 80C. The MGMT activity was measured as described previously 24 ; by incubating cell extracts, diluted in assay buffer [50 mM Tris HCl pH 8.3 ; , 0.5 mM EDTA, and 1 mM DTT], with DNA containing O6-[Methyl-3H]methylguanine 1500 dpm ; at 37C for 90 min, and the reaction was terminated by chilling on ice and adding 200 g of calf thymus DNA in 300 l of 80 EDTA pH 6.0 ; . The [Methyl-3H] that had been transferred to protein was solubilized by 10 l mg ml proteinase K in 1 CaCl2 ; for 60 min at 37C. The DNA was removed by precipitation with 3% cetyltrimethylammonium bromide and centrifugation. The radioactivity in the supernatant was determined by liquid scintillation counting, and the fmol of MGMT per cell was calculated from the stoichiometry of the transfer of methyl-3H groups to the protein and specific activity of the substrate. Growth Inhibition Assays. Cells were seeded into 96well plates at a density shown previously to give exponential growth throughout the exposure period, i.e., HCT116 and HCT Chr3 103; A2780, 2 103; CP70, 500; CP70-ch3, 103 3 and CP70-ch2 1.5 10 cells well in 100- l tissue culture medium. After attachment overnight, the cells were exposed to varying concentrations of temozolomide, topotecan, or cisplatin in the presence or absence of 400 nM AG14361 and or 10 M for 5 days, then fixed and stained with sulforhodamine B as described previously 29 ; . The concentration required to inhibit cell growth by 50% GI50 ; was calculated from point-to-point graphs using GraphPad Prism San Diego, CA ; software. The potentiation factor at 50% growth inhibition was calculated from the ratio of the GI50 of the cytotoxic drug temozolomide, topotecan, or cisplatin ; alone to the GI50 of the drug plus resistance modifier BG or AG14361 ; DNA Strand Break Assay by Alkaline Elution. The alkaline elution technique was used for the quantitative analysis of DNA single-strand breakage in which fragments of DNA were separated on the basis of size using polycarbonate filters, which are neither protein nor DNA adsorbent, as described by Kohn et al. 30 ; . The alkaline elution assay has been shown previously to have a sensitivity of 1 DNA lesion 107 nucleotides 30 ; . To increase the precision of the assay, samples were coeluted with an internal standard consisting of irradiated DNA. Exponentially growing CP70-ch3 or CP70-ch2 cells were labeled with [2-14C]-thymidine 0.74 KBq ml ; for 24 h, followed by 4 h fresh medium, then treated for 4 h with temozolomide 500 M ; with or without AG14361 400 nM ; . Cells were lysed on the polycarbonate filters, and DNA was coeluted with [methyl-3H]-thymidine 3.7 KBq ml ; -labeled DNA from internal standard cells exposed to 3 Gy -radiation using a 137Cs source, Gammacell 1000 elite; Nordion International, Inc., Kanata, Canada ; . Relative elution values of treated samples compared with and codeine.
Stage II-IV Ovarian Cancer Guideline Question What is the optimal postoperative chemotherapy regimen for women with stage II, III micro or macro ; or IV epithelial ovarian cancer who are newly diagnosed and who have not previously received chemotherapy? Target Population These recommendations apply to postoperative patients with newly diagnosed stage II, III with or without measurable disease after surgery ; or IV epithelial ovarian cancer who have not been previously treated with chemotherapy. Recommendations Update Intravenous carboplatin with or without paclitaxel or docetaxel is the recommended postoperative chemotherapy regimen for newly diagnosed stage II-IV epithelial ovarian cancer. - Paclitaxel in combination with carboplatin is associated with greater neurotoxicity than docetaxel and carboplatin, however, the combination of docetaxel and carboplatin is associated with more myelosuppression than paclitaxel and carboplatin. The differences in the toxicity profiles should be discussed with patients when choosing the most appropriate regimen. Intravenous cisplatin plus paclitaxel may also be considered as a treatment option and cisplatin.
Number of completed deals dropping from 75 in 2005 to 73 in 2006, the value of completed In 2006, the biotech industry deals increased from billion enjoyed another successful year to billion driven by eight of venture capital and IPO fund deals in excess of billion raising, partnership deals, and each. The billion merger and acquisitions plus deals included M&A ; activity. European biotechnology deals 1997-2006 AztraZeneca plc's Globally, .6 billion acquisition of Year Alliances M&As Total was raised by biotech Cambridge Antibody companies. However, 2006 337 64 Technology for this was matched by 2005 328 66 .3 billion. 30 billion in capital 2004 280 42 Compared with the r e t financial investor, big shareholders as a result 2003 200 39 pharma companies of M&A activity. This 2002 505 30 see greater value in a means that the 2001 607 55 biotech because they institutions, private have the marketing 2000 485 54 equity houses and and distribution venture capital 1999 336 46 infrastructure to replenished their funds 1998 207 19 launch a new product to invest. 1997 237 39 successfully. The global financing Therefore, the value a Sources: Ernst & Young, BioCentury, activity is being driven financial investor by the demand for new and company news through NewsAnalyzer ; prices into a biotech product to fill the big Only biotech-biotech and biotech-pharma deals included business is reduced pharma's spartan by the increased risk pipelines. However, it is not pharmas needing to develop and only big pharma that is making launch new products in the and funding required to fund a acquisitions but the larger market is the premium price successful large scale product biotech companies a r e they are prepared to pay launch. themselves maturing to the compared with biotech company point that acquisition activity is public market valuations. For IPO market being used to fill gaps in their deals over 0 million, trade product pipeline and to meet buyers paid an `innovation The IPO market saw 47 increasing s h a premium' of 60% over market companies come to market Despite the globally compared with 44 in expectations. This has led to value in 2006. unprecedented deal activity in the sector. However, deal values were not driven by one or two mega deals as in previous years. The consequence of big 11 and cogentin.
1. Cannistra, S. A. Cancer of the ovary. N. Engl. J. Med., 329: 1550 1559, Neijt, J. P. Ovarian cancernew insights into systemic therapy. Eur. J. Cancer, 31A: 823 824, Piccart, M. J., Du, B. A., Gore, M. E., Neijt, J. P., Pecorelli, S., and Pujade-Lauraine, E. A new standard of care for treatment of ovarian cancer. Eur. J. Cancer, 36: 10 12, Bookman, M. A., Malmstrom, H., Bolis, G., Gordon, A., Lissoni, A., Krebs, J. B., and Fields, S. Z. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol., 16: 33453352, 1998. Brogden, R. N., and Wiseman, L. R. Topotecan. A review of its potential in advanced ovarian cancer. Drugs, 56: 709 723, McGuire, W. P., Blessing, J. A., Bookman, M. A., Lentz, S. S., and Dunton, C. J. Topotecan has substantial antitumor activity as first-line!
Reference: pace a, savarese a, picardo m, et al neuroprotective effect of vitamin e supplementation in patients treated with cisplatin chemotherapy and cognex.
Docetaxel-based chemotherapy appears to have considerable promise in advanced gastric cancer. In phase II studies of single agent docetaxel, response rates RRs ; of 17% to 24% have been achieved in previously untreated patients. Importantly, RRs of 20% to 22% are seen in second-line treatment. Work by a Swiss and Italian collaborative group has shown that the combination of docetaxel 85 mg m2 with cisplatin 75 mg m2 every 3 weeks is quite active, achieving an RR of 55% and median survival of 9 months. Hematotoxicity was the main adverse event but was manageable. In other respects the docetaxel cisplatin doublet TC ; was relatively well tolerated. The same group demonstrated that continuous infusion of 5-fluorouracil 5-FU ; 300 mg m2 can be given on 2 weeks out of 3 to patients receiving TC. The addition of 5-FU, by this schedule, to TC TCF ; does not increase hematological toxicity, and does not compromise the tolerability of TC. An overall RR of 55% has been reported with TCF. A randomized phase II comparison of TC or TCF versus an ECF epirubicin cisplatin 5-FU ; control arm is ongoing and should lead to a randomized phase III trial comparing TC or TCF with ECF. In an already completed international randomized phase II comparison of TC versus TCF TAX-325 ; , the threedrug combination proved significantly more active RR 54% versus 32% with TC, among patients treated per protocol ; . Time to progression was also longer for TCF. Gastrointestinal but not hematological ; toxicity was less with TC. TCF was chosen for ongoing phase III comparison against a control 5-FU cisplatin arm. It is possible that data from these randomized studies will confirm the value of docetaxel-based chemotherapy in advanced gastric cancer and that docetaxel combinations will also be effective in the multidisciplinary efforts to cure earlier stage cancer and cladribine.
Cisplatin nephrotoxicity mechanism
Cisplatinn, csiplatin, cidplatin, c8splatin, cissplatin, ciplatin, cisplahin, cusplatin, cisplatiin, cislatin, cispaltin, cisplatim, clsplatin, cisplqtin, icsplatin, cispla6in, ccisplatin, cisplarin, ciisplatin, cksplatin, cizplatin, cjsplatin, cisplayin, cisplstin, cisolatin, cispkatin, cispatin, cixplatin, cisplat8n, cisplati, cisplaton, cisplain, cisplatn, cis0latin, cisplwtin, cispla5in.
Cisplatin drug interactions
Cisplatin xeloda, cisplatin nephrotoxicity mechanism, cisplatin drug interactions, cisplatin water and cisplatin pdf. Cisplatin resistant, pemetrexed cisplatin nsclc, camptosar and cisplatin and cisplatin and etoposide with radiation or cisplatin price.
|
